Deucrictibant Data Highlighted in Multiple Presentations at

ZUG, Switzerland, May 06, 2023 -- Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today announced... | May 6, 2023

Related Keywords

Israel , Canada , United States , Netherlands , United Kingdom , Ukraine , Switzerland , Hungary , Russia , Budapest , Anna Valerieva , Remys Peterson , Anne Lesage , Henriette Farkas , Brigitte Loenders , Marcus Maurer , Peng Lu , Marca Riedl , Globenewswire Inc , European Union , Early Development , Exchange Commission , Angioedema Workshop , Chief Medical Officer , Chief Early Development Officer , Antagonist Deucrictibant , Against Bradykinin Effects , Healthy Volunteers Predicts , Its Clinical Effects , Hereditary Angioedema Attacks , Topline Results , Mean Symptom Complex Severity , Treatment Outcome Score , Statement Regarding Forward Looking , Annual Report , Beller Head , Pharvarisnv Stock Exchange , News , Information , Press Release , Bay , 023 , Pharvaris , Company , Developing , Mural , Antagonists , O , Treat , End , Prevent , Hereditary , Angioedema , Oday Phvs Nl00150005y4 ,